TII
24.5.2022 08:02:03 CEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced that its Directed Energy Research Center (DERC) has launched a state-of-the-art facility in Tawazun Industrial Park (TIP), a regional hub for strategic businesses in the safety and security sector offering world-class business infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220523005302/en/
The facility comprises seven distinct workshops and five specialized laboratories. Each caters to a specific research domain from mechanical and electronics workshops, prototype test area, coil winding, armature filling, dielectric testing, and acoustic prototyping lab. The laboratories are Pulse Power Lab, Semi-Anechoic Chamber, Tempest Chamber, Acoustic Lab, and Laser Development Lab.
The facility hosts three mobile research laboratories that can be used in conjunction with the primary laboratories or be deployed in the field for outdoor testing, including two Electromagnetic Mobile Labs and a Mobile Laser Lab. Applications DERC focuses on include High-Power ElectroMagnetics (HPEM) and Electromagnetic Compatibility (EMC) testing. DERC also undertakes innovative research in the HPEM and Pulsed Power domain, along with prequalification tests for multiple industries in the region.
A first for the GCC, DERC’s facility conducts industry-leading Radio Frequency testing to manufacture and characterize high power, solid-state devices. The facility also carries out highly sensitive Acoustic experiments that require a high degree of isolation from environmental sound and vibrations, supporting development and characterization of unusual acoustic transmitters and sensors.
The controlled environment in the labs identifies involuntary sound sources in complex electronic systems that might lead to side-channel leakage. DERC’s custom-developed optical vibration analysis tools can examine mechanical system behavior across a wide range of frequencies.
Additionally, the Center has also introduced groundbreaking Signal Electronics & Acoustics (SEA) prototyping to facilitate the local development of advanced solutions like small/high-density RF and acoustic devices. The facility can undertake soldering, complex mechanical assembly, testing while advancing prototyping in 3D printing.
DERC’s Mobile Laser lab is the first of its kind in the region to conduct laser experiments outdoors to explore propagation of a high-power laser and study the effect on targets at a distance in the arid Gulf environment. Emitting a multi-kW continuous laser, the lab is equipped with a telescope mounted on a pan-tilt, focusing a beam over a distance ranging from 200 m to 2,000 m. Connected to an electrical generator, the mobile lab is designed to be used autonomously outdoors under extreme temperatures of up to 50°C.
Speaking on the new facility, Dr. Ray O. Johnson, CEO of Technology Innovation Institute (TII) and Acting CEO, ASPIRE, said: “At TII, we are committed to attracting global talent to our research centers. Given this priority, we are proud to witness DERC’s phenomenal achievement with this facility. Such innovative hubs draw a growing number of researchers as well as customers keen to benefit from testing capabilities across varied sectors.”
Dr. Chaouki Kasmi, Chief Researcher, Directed Energy Research Center (DERC), said: “We are excited to finally witness the launch and cutting-edge capabilities of this new facility that will offer us a distinct advantage while giving the UAE much-needed autonomy when it comes to ensuring comprehensive testing and establishing a reliable supply chain.”
The Center’s achievement of bringing together multiple core capabilities under one roof provides opportunities to take HPEM testing to greater heights while enabling the testing of high-power lasers in compact environments.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005302/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom